Literature DB >> 15968265

A clinician's paradigm in the treatment of psoriasis.

Mark Lebwohl1.   

Abstract

Psoriasis is a chronically recurring inflammatory disease that affects the skin, scalp, and joints. It ranges in severity from mild to severe, and patients with moderate to severe disease experience significant deterioration in quality of life. The goals of psoriasis treatment are to gain initial and rapid control of the disease process, decrease the percentage of body surface area involved, decrease plaque lesions, achieve and maintain long-term remission, minimize adverse events, and improve patient quality of life. Therapy varies depending on disease severity and spread and will shift from control of acute flares to long-term maintenance. Topical treatment for mild psoriasis includes the use of topical corticosteroids, calcipotriene, tazarotene, topical tars, anthralin, and keratolytics. Treatment of moderate to severe psoriasis includes systemic therapies, such as methotrexate, acitretin, cyclosporine, and biologic agents. Treatment can be effected using combination, rotational, or sequential regimens. Treatment algorithms developed by a 2002 consensus conference are described. Because some degree of therapy will always be necessary, ranging from maintenance of long-term remission to control of acute psoriasis flares, each patient requires an individualized plan.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15968265     DOI: 10.1016/j.jaad.2005.04.031

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  15 in total

1.  Use of Topical Coal Tar Foam for the Treatment of Psoriasis in Difficult-to-treat Areas.

Authors:  Joshua A Zeichner
Journal:  J Clin Aesthet Dermatol       Date:  2010-09

Review 2.  [Penile dermatoses].

Authors:  K Kühborth; G Haidl; J-P Allam
Journal:  Urologe A       Date:  2015-05       Impact factor: 0.639

3.  Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis.

Authors:  S Indhumathi; Medha Rajappa; Laxmisha Chandrashekar; P H Ananthanarayanan; D M Thappa; V S Negi
Journal:  Eur J Clin Pharmacol       Date:  2017-04-25       Impact factor: 2.953

4.  Coal tar 2% foam in combination with a superpotent corticosteroid foam for plaque psoriasis: case report and clinical implications.

Authors:  Amylynne J Frankel; Joshua A Zeichner; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2010-10

5.  A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Ammonium Lactate Lotion 12% and Halobetasol Propionate Ointment 0.05% in the Treatment and Maintenance of Psoriasis.

Authors:  Jason J Emer; Amylynne Frankel; Andrew Sohn; Mark Lebwohl
Journal:  J Clin Aesthet Dermatol       Date:  2011-02

6.  Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.

Authors:  Howa Yeung; Joy Wan; Abby S Van Voorhees; Kristina Callis Duffin; Gerald G Krueger; Robert E Kalb; Jamie D Weisman; Brian R Sperber; Bruce A Brod; Stephen M Schleicher; Bruce F Bebo; Daniel B Shin; Andrea B Troxel; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2012-07-28       Impact factor: 11.527

7.  Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice.

Authors:  K Callis Duffin; H Yeung; J Takeshita; G G Krueger; A D Robertson; A B Troxel; D B Shin; A S Van Voorhees; J M Gelfand
Journal:  Br J Dermatol       Date:  2014-03       Impact factor: 9.302

Review 8.  Topical treatments for scalp psoriasis.

Authors:  Richard B Warren; Benjamin C Brown; Christopher E M Griffiths
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Topical alpha-selective p38 MAP kinase inhibition reduces acute skin inflammation in guinea pig.

Authors:  Satyanarayana Medicherla; Jing Ying Ma; Mamtha Reddy; Irina Esikova; Irene Kerr; Fabiola Movius; Linda S Higgins; Andrew A Protter
Journal:  J Inflamm Res       Date:  2010-02-18

10.  Biologics in dermatologic therapy - an update.

Authors:  Arijit Coondoo
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.